]> 2026-04-12T05:40:26-07:00 TTF 0 en The primary side effect is localized skin irritation beneath the transducer arrays, which is generally manageable with topical treatments and proper skin care. Unlike traditional chemotherapies, TTFields do not cause systemic toxicities such as immunosuppression or organ dysfunction. 2025-03-09T04:08:08Z 2460743.6723148 TTF 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has clinical trial explanation","TTFields have undergone extensive clinical evaluation, including the EF-14 Phase III trial, which demonstrated a significant survival benefit in newly diagnosed glioblastoma patients when combined with temozolomide. Ongoing Phase III trials are investigating its efficacy in other cancers such as non-small cell lung cancer, ovarian cancer, and pancreatic cancer."] TTF# ERR3019b4979f53631ee3912d6416218f93 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has Usefulness Explanation","TTFields offer a novel, non-invasive treatment modality that has been clinically proven to extend both progression-free and overall survival in glioblastoma patients, with minimal systemic side effects. Its integration into standard care practices provides an additional therapeutic option for patients with limited alternatives."] TTF# ERR0de0b09fdf871942cb9b8a10a8978dce